1. 1. Toyoda H, Atsukawa M, Watanabe T, et al. Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 35: 855-861, 2020.
2. 2. Okada M, Oeda S, Katsuki N, et al. Recommendations from primary care physicians, family, friends and work colleagues influence patients' decisions related to hepatitis screening, medical examinations and antiviral treatment. Exp Ther Med 19: 2973-2982, 2020.
3. 3. Furukawa N, Kawaguchi Y, Oeda S, et al. Current management practices for HBs antigen or anti-HCV antibody positive individuals in non-hepatology departments at a university hospital. Kanzo 54: 307-316, 2013 (in Japanese, Abstract in English).
4. 4. Hidaka I, Enomoto M, Sato S, et al. Establishing efficient systems through electronic medical records to promote intra-hospital referrals of hepatitis virus carriers to hepatology specialists: a multicenter questionnaire-based survey of 1,281 healthcare professionals. Intern Med 60: 337-343, 2021.
5. 5. Setoyama H, Korenaga M, Kitayama Y, et al. Nationwide survey on activities of regional core centers for the management of liver disease in Japan: cumulative analyses by the Hepatitis Information Center 2009-2017. Hepatol Res 50: 165-173, 2020.